Immunocore Holdings (IMCR) Gross Margin (2021 - 2026)
Immunocore Holdings (IMCR) posted Gross Margin of 99.59% for Q1 2026, up 2.24% sequentially from 97.41% in Q4 2025, and up 48.0% YoY from 67.29% in Q1 2025.
Powered by 
Analysis
Immunocore Holdings (IMCR) Gross Margin (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Gross Margin for 6 years, with the latest figure at 99.59% in Q1 2026.
- Quarterly Gross Margin rose 48.0% year-over-year to 99.59% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.86% (down 14.0% YoY) and the FY2025 annual result came in at 98.73%, down 39.0% from the prior year.
- Gross Margin climbed to 99.59% in Q1 2026 per IMCR's latest filing, from 97.41% in the prior quarter.
- Over five years, Gross Margin peaked at 99.85% in Q3 2022 and troughed at 97.41% in Q4 2025.
- A 5-year average of 99.18% and a median of 99.54% in 2025 frame the typical range for Gross Margin.
- The widest YoY moves for Gross Margin: up 120 bps in 2025, down 219 bps in 2025.
- Over 5 years, Gross Margin stood at 99.77% in 2022, then decreased by 0 bps to 99.71% in 2023, then retreated by 0 bps to 99.61% in 2024, then dropped by 2 bps to 97.41% in 2025, then gained by 2 bps to 99.59% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 99.59%, 97.41%, and 99.51% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn | 99.06% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 99.06% |
| Mar 31, 2026 | 99.59% |
| Dec 31, 2025 | 97.41% |
| Sep 30, 2025 | 99.51% |
| Jun 30, 2025 | 98.94% |
| Mar 31, 2025 | 99.11% |
| Dec 31, 2024 | 99.61% |
| Sep 30, 2024 | 99.44% |
| Jun 30, 2024 | 97.74% |
| Mar 31, 2024 | 99.65% |
| Dec 31, 2023 | 99.71% |
| Sep 30, 2023 | 99.57% |
| Jun 30, 2023 | 98.17% |
| Mar 31, 2023 | 99.60% |
| Dec 31, 2022 | 99.77% |
| Sep 30, 2022 | 99.85% |
| Jun 30, 2022 | 99.23% |
| Dec 31, 2021 | 100.00% |
| Sep 30, 2021 | 100.00% |